A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB
B A C K G R O U N D: Treatment for TB is lengthy and toxic, and new regimens are needed. M E T H O D S: Participants with pulmonary drug-susceptible TB (DS-TB) were randomised to receive: 200 mg pretomanid (Pa, PMD) daily, 400 mg moxifloxacin (M) and 1500 mg pyrazinamide (Z) for 6 months (6Pa200MZ)...
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
International Union Against Tuberculosis and Lung Disease
2021
|
Series: | International Journal of Tuberculosis and Lung Disease
|
Subjects: | |
Online Access: | View Fulltext in Publisher View in Scopus |